Peptide vaccination activating Galectin-3-specific T cells offers a novel means to target Galectin-3-expressing cells in the tumor microenvironment

Cytotoxic T cells isolated from healthy donors and cancer patients kill TGFβ-expressing cancer cells in a TGFβ-dependent manner

(2021) Morten Orebo Holmström et al.   Cellular & Molecular Immunology

Inhibition of galectin‐3 augments the antitumor efficacy of PD‐L1 blockade in non‐small‐cell lung cancer

(2021) Hongxin Zhang et al.   FEBS Open Bio

Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor

(2021) Brendan D Curti et al.   Journal for ImmunoTherapy of Cancer

Enhancing adoptive CD8 T cell therapy by systemic delivery of tumor associated antigens

(2021) Ditte E. Jæhger et al.   Scientific Reports

Regulatory T cells in cancer immunosuppression — implications for anticancer therapy

(2019) Yosuke Togashi et al.   Nature Reviews Clinical Oncology

The Balance Players of the Adaptive Immune System

(2018) Mads Hald Andersen   CANCER RESEARCH

The role of Galectin-3 in modulating tumor growth and immunosuppression within the tumor microenvironment

(2018) Mohammad Farhad et al.   OncoImmunology

Complimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors

(2018) Erika J. Crosby et al.   OncoImmunology

Durable Clinical Responses and Long-Term Follow-Up of Stage III–IV Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With IDO Peptide Vaccine in a Phase I Study—A Brief Research Report

(2018) Julie Westerlin Kjeldsen et al.   Frontiers in Immunology

The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy

(2017) Shamaila Munir Ahmad et al.   OncoImmunology

Frequent adaptive immune responses against arginase-1

(2017) Evelina Martinenaite et al.   OncoImmunology

Galectin 3 as a guardian of the tumor microenvironment

(2016) Peter P. Ruvolo   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Clinical significance of galectin-3 in patients with adult acute myeloid leukemia: a retrospective cohort study with long-term follow-up and formulation of risk scoring system

(2016) Na Gao et al.   LEUKEMIA & LYMPHOMA

CCL22-specific T Cells: Modulating the immunosuppressive tumor microenvironment

(2016) Evelina Martinenaite et al.   OncoImmunology

M1 and M2 macrophages derived from THP-1 cells differentially modulate the response of cancer cells to etoposide

(2015) Marie Genin et al.   BMC CANCER

Functional and molecular characterisation of EO771.LMB tumours, a new C57BL/6-mouse-derived model of spontaneously metastatic mammary cancer

(2015) C. N. Johnstone et al.   Disease Models & Mechanisms

Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells

(2015) T. Kouo et al.   Cancer Immunology Research

A Short Treatment with Galactomannan GM-CT-01 Corrects the Functions of Freshly Isolated Human Tumor-Infiltrating Lymphocytes

(2014) N. Demotte et al.   CLINICAL CANCER RESEARCH

Differential Roles of Galectin-1 and Galectin-3 in Regulating Leukocyte Viability and Cytokine Secretion

(2014) S. R. Stowell et al.   JOURNAL OF IMMUNOLOGY

Galectin-3 as a Marker and Potential Therapeutic Target in Breast Cancer

(2014) Hao Zhang et al.   PLoS One

Extracellular Galectin-3 in Tumor Progression and Metastasis

(2014) Anneliese Fortuna-Costa et al.   Frontiers in Oncology

Higher bone marrow LGALS3 expression is an independent unfavorable prognostic factor for overall survival in patients with acute myeloid leukemia

(2013) C.-L. Cheng et al.   BLOOD

HLA-Restricted CTL That Are Specific for the Immune Checkpoint Ligand PD-L1 Occur with High Frequency in Cancer Patients

(2013) S. Munir et al.   CANCER RESEARCH

Regulation of galectin-3-induced apoptosis of Jurkat cells by bothO-glycans andN-glycans on CD45

(2013) Jing Xue et al.   FEBS LETTERS

Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion

(2013) Yared Hailemichael et al.   NATURE MEDICINE

The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4+T cells

(2013) Shamaila Munir et al.   OncoImmunology

Natural CD4+ T-Cell Responses against Indoleamine 2,3-Dioxygenase

(2012) Shamaila Munir et al.   PLoS One

Galectin-3 (Gal-3) induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemia

(2011) M. Yamamoto-Sugitani et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Immune Suppression in Tumors as a Surmountable Obstacle to Clinical Efficacy of Cancer Vaccines

(2011) Grégoire Wieërs et al.   Cancers

Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators

(2010) R. B. Sorensen et al.   BLOOD

Response definition criteria for ELISPOT assays revisited

(2010) Z. Moodie et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

A Galectin-3 Ligand Corrects the Impaired Function of Human CD4 and CD8 Tumor-Infiltrating Lymphocytes and Favors Tumor Rejection in Mice

(2010) N. Demotte et al.   CANCER RESEARCH

Galectin-3 regulates T-cell functions

(2009) Daniel K. Hsu et al.   IMMUNOLOGICAL REVIEWS

Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates

(2008) Carolina Berger et al.   JOURNAL OF CLINICAL INVESTIGATION